Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined
- PDF / 541,318 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 104 Downloads / 224 Views
ORIGINAL RESEARCH
Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec– Liraglutide (Ideglira) Luciano Zenari . Andrea Da Porto . Lorena De Moliner . Francesca Lugli . Valeria Guazzoni . Gloria Groppelli . Laura Molteni . Massimo Bracaccia . Vera Frison . Natalino Simioni . Barbara Bonsembiante . Cesare Miranda . Annunziata Lapolla Received: August 25, 2020 / Accepted: October 6, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA liraglutide (IDegLira) represents an improvement to this therapy. We have conducted a real-
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13300020-00945-4) contains supplementary material, which is available to authorized users. L. Zenari (&) Unita` Operativa di Diabetologia, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, VR, Italy e-mail: [email protected] A. Da Porto Ambulatorio Diabetologia, Clinica Medica, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy L. De Moliner Ambulatorio Diabetologico, Unita` Operativa Geriatria, Ospedale S. Maria del Carmine, Rovereto, TN, Italy F. Lugli Unita` Operativa Complessa Diabetologia Territoriale, Azienda Unita` Sanitaria Locale (AUSL) Ferrara, Ferrara, FE, Italy
world evidence study in Italian patients with T2DM to evaluate whether the encouraging clinical trial results obtained with IDegLira, which became available in Italy in January 2018, can be confirmed in Italian clinical practice. Methods: This was a multicenter, retrospective, observational study in patients with T2DM treated with IDegLira from January to December 2018. Prior to the initiation of IDegLira therapy, patients were treated with BI with or without one or more concomitant oral antidiabetic drugs (BOT group) or according to the basal bolus protocol (BI and rapid-acting insulin treatment; BB group).
V. Guazzoni G. Groppelli Unita` Operativa Diabetologia, Ospedale Maggiore, Lodi, LO, Italy L. Molteni Centro Diabetologico, Ospedale Sacra Famiglia Fatebenefratelli, Erba, CO, Italy M. Bracaccia Diabetologia, Dipartimento di Medicina Interna, Ospedale Santa Maria della Stella, Orvieto, TR, Italy V. Frison N. Simioni Servizio di Diabetologia, Distretto 4 ‘‘Alta Padovana’’, Cittadella, PD, Italy V. Frison N. Simioni Azienda ULSS 6 Euganea, Padova, PD, Italy
Diabetes Ther
Results: A total of 244 patients were included in the present study, of whom 186 were in the BOT group and 58 in the BB group. Following the switch to IDegLira therapy, glycemic control improved in both groups, with significant reductions in glycated hemoglobin after 6 and 12 months of treatment in the BOT group and after 6
Data Loading...
